Empagliflozin and Sympathetic Nerve Traffic

Sponsor
Profil Institut für Stoffwechselforschung GmbH
Study ID
NCT03254849
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin — DRUG
    1 tablet
  • Hydrochlorothiazide 25 mg — DRUG
    1 tablet

Study Details

In this study the effects of the Inhibition of the Sodium-Glucose Linked Transporter 2 in the kidney with empagliflozin compared to hydrochlorothiazide on blood pressure and on central sympathic nervous activity will be examined.

Key Dates

Start date
Dec 8, 2017
Status verified
Jul 2020
Primary completion
Apr 20, 2020
Completion
Apr 20, 2020

Study Design

Enrollment
75 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: empagliflozin 25 mg
    Each patient will take 2 tablets each day to ensure double-blind Treatment. Arm 1: 25 mg/d empagliflozin + hydrochlorothiazide placebo
  • Experimental: hydrochlorothiazide 25 mg
    Each patient will take 2 tablets each day to ensure double-blind Treatment. Arm 2: 25 mg/d hydrochlorothiazide + empagliflozin placebo

Primary Outcome Measure

Blood Pressure reduction [ Time Frame: 6 weeks ]

Related Studies